## ABSTRACT

The present invention provides compounds represented by general formula (I):

$$\mathbb{R}^{4}$$
 $\mathbb{R}^{3}$ 
 $\mathbb{R}^{2}$ 
 $\mathbb{R}^{5}$ 
 $\mathbb{R}^{6}$ 
 $\mathbb{R}^{6}$ 
 $\mathbb{R}^{1}$ 
 $\mathbb{R}^{6}$ 
 $\mathbb{R}^{2}$ 
 $\mathbb{R}^{2}$ 
 $\mathbb{R}^{2}$ 
 $\mathbb{R}^{2}$ 
 $\mathbb{R}^{2}$ 

5

10

15

or pharmaceutical acceptable salts thereof, wherein  $R^1$  is hydrogen or lower alkyl;  $R^2$  is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, arylalkenyl, aryloxy-lower alkyl, heteroaryl, heteroaryl-lower alkyl, etc;  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are each hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, lower alkoxy, hydroxy, aryl, etc; provided that at least one of  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  is other than hydrogen. Compound (I) of the present invention shows a potent adenosine  $A_{2A}$  receptor antagonistic activity, and are useful for treating or preventing a disease mediated by adenosine  $A_{2A}$  receptors such as motor function disorders, depression, anxiety disorders, cognitive function disorders, cerebral ischemia disorders, restless legs syndrome and the like.